What is Kyntra Bio, Inc. (KYNB)?

Kyntra Bio, Inc. (KYNB) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of KYNB?

The current price of KYNB is $4.57. Prices are updated in real time on Stocks360.

What is KYNB's price-to-earnings (PE) ratio?

KYNB's trailing twelve-month PE ratio is 0.08, based on current price and earnings per share data available on Stocks360.

What is KYNB's market capitalization?

KYNB's market capitalization is $18,504,478.00, placing it in the small-cap tier.

Kyntra Bio, Inc. (KYNB)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$4.57

Market Cap

$18.50M

PE (TTM)

0.08

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.05

Day Range

$4.48 – $4.70

52-wk Range

$4.32 – $11.39

Avg Volume

N/A

Volume

24.41K

Kyntra Bio, Inc. (KYNB) is a publicly traded company in the Healthcare sector. Latest price: $4.57. Market cap $18.50M. Trailing PE 0.08. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 8 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-31 · $11.12 2026-10-30 · $4.57 (-58.90%)

Earnings

Most Recent

Aug 13, 2026

EPS $2.96 vs est. $-3.18

Beat by $6.14

Next Earnings

Nov 9, 2026

EPS estimate $-3.55

Proprietary Signals

Signal snapshot temporarily unavailable.

About Kyntra Bio, Inc.

Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	0.08×
P/S (TTM)	4.01×
P/B	-0.61×
PEG	0.00×
P/FCF (TTM)	-0.49×
EV / EBITDA	0.34×
EV / Sales	-6.96×
Earnings Yield	990.26%
Free Cash Flow Yield	-205.69%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$32.14M
Net Income (TTM)	$183.24M
Free Cash Flow (TTM)	-$28.77M
Net Debt	-$50.64M
Working Capital	$60.78M
Gross Margin	18.15%
Operating Margin	-1101.02%
Net Margin	3967.77%
Return on Equity	-605.53%
Return on Invested Capital	-78.16%